Hims & Hers (NYSE: HIMS) Crashes 11.98% on Q1 Miss and Weak Forward Guidance

Hims & Hers Health Inc. (NYSE: HIMS) collapsed 11.98% to $25.65 on Tuesday, May 12, 2026, after the telehealth company reported a net loss in Q1 2026 alongside weak forward guidance. The sharp decline erased investor confidence despite the company's rapid revenue growth, exposing profitability concerns that markets had previously overlooked.

Q1 2026 At a Glance

• Stock price fell to $25.65 from $29.14 at prior close, a loss of $3.49 per share
• Q1 2026 result: net loss reported; revenue missed analyst expectations
• Market capitalization: approximately $6.1 billion
• Forward guidance: weak outlook provided

What Drove the Results

Hims & Hers reported a net loss in Q1 2026, signaling a deterioration in unit economics despite 3.8% revenue growth (TTM). The company's negative operating margin of -12.88% indicates that the telehealth business model remains unprofitable at scale, raising questions about the sustainability of growth. The weak forward guidance compounded disappointment, suggesting management sees limited near-term path to profitability.

The earnings miss reflects intensifying competitive pressures in the direct-to-consumer telehealth space and potential headwinds in specific medication categories facing regulatory or reimbursement pressures. Hims' reliance on high-margin categories like GLP-1 appetite suppressants and sexual wellness treatments creates vulnerability to competitive entry and pricing pressure. The market's sharp selloff indicates investors had been betting on profitability inflection that is not materializing.

Investor Takeaway

Hims & Hers' 11.98% plunge underscores the market's intolerance for unprofitable growth trajectories, even in high-velocity categories. With a net profit margin of -0.56% (TTM) and an operating margin of -12.88%, the company is burning capital to acquire customers. The wide gap between forward P/E (19.36x) and trailing P/E (51.76x) reflects investor expectations for dramatic profit expansion that the Q1 results and guidance suggest may not arrive soon. Value-oriented investors should await clearer evidence of a path to sustainable profitability before reconsidering the stock.